title: European Pharmaceutical Pricing and Reimbursement--SMi's 21st Annual Meeting (October 5-6, 2015--London, UK).
abstract: Translating perceived market value for pharmaceutical products into a willingness to pay remains the key factor in ensuring market access and return on investment. How price is managed in the context of new market entrants or new approval settings can create complex challenges, and further complexity is added through diverse global reimbursement structures and the myriad of stakeholders involved at every step of value identification. SMi's 21st Annual Meeting on European Pricing and Reimbursement presented a program focused on the measures being taken by European healthcare systems as they seek to facilitate access to the latest treatments while delivering value for payers and patients. Supporting patient access to life-changing medicines is a challenge, and funders are responding in many different ways; however, while the pharma industry continues to focus its efforts on high cost drugs that treat diseases of the few, the disconnect will be not be resolved. The speakers and delegates at the annual meeting believe success is possible by focusing on value for patients, driven by provider experience, scale and learning. Instead of simply lowering costs, companies, providers and payers can more adequately contribute to the goals of funders as well as the treatment needs of patients.
authors.affiliation: Thomson Reuters, London, UK. alexandra.kibble@thomsonreuters.com.
authors.forename: A
authors.initials: A
authors.lastname: Kibble
authors.affiliation: Thomson Reuters, London, UK. paul.dsouza@thomsonreuters.com.
authors.forename: P
authors.initials: P
authors.lastname: D'Souza
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics; D003365:Costs and Cost Analysis; D016527:Drug Costs; D004345:Drug Industry; D005060:Europe; D007349:Insurance, Health, Reimbursement; D009965:Orphan Drug Production / Q000191:economics; D013673:Technology Assessment, Biomedical
chemical_list: D000970:Antineoplastic Agents
keywords: Cancer drug fund; Health technology assessments; Pharmaceutical pricing; Reimbursement